Access to diabetes drugs in New Zealand is inadequate

N Z Med J. 2016 Jun 10;129(1436):6-9.

Authors

Jeremy Krebs¹, Kirsten J Coppell, Pip Cresswell, Michelle Downie, Paul Drury, Ann Gregory, Timothy Kenealy, Catherine McNamara, Steven Cm Miller, Kate Smallman

Affiliation

¹ Endocrine, Diabetes and Research Centre, Wellington Regional Hospital, Wellington, New Zealand. jeremy.krebs@ccdhb.org.nz.

PMID: 27355224

No abstract available

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Dipeptidyl-Peptidase IV Inhibitors / economics
Dipeptidyl-Peptidase IV Inhibitors / supply & distribution
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
Drug Costs
Financing, Government
Glucagon-Like Peptide 1 / agonists
Glycated Hemoglobin / metabolism
Health Services Accessibility / economics
Healthcare Financing
Humans
Hypoglycemia / chemically induced
Hypoglycemic Agents / economics
Hypoglycemic Agents / supply & distribution*
Hypoglycemic Agents / therapeutic use
New Zealand
Practice Guidelines as Topic
Sodium-Glucose Transporter 2 Inhibitors

Substances

Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin A
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
hemoglobin A1c protein, human
Glucagon-Like Peptide 1